Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells

Oncotarget

Volumn 6, Issue 8, 2015, Pages 6326-6340

  Hou, Zhi Jie ^a,b   Luo, Xi ^a,b   Zhang, Wei ^a,b   Peng, Fei ^a,b   Cui, Bai ^a,b   Wu, Si Jin ^c   Zheng, Fei Meng ^a,b   Xu, Jie ^a,b   Xu, Ling Zhi ^a,b   Long, Zi Jie ^d   Wang, Xue Ting ^a,b   Li, Guo Hui ^e   Wan, Xian Yao ^a   Yang, Yong Liang ^b   Liu, Quentin ^a,b  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^d SUN YAT SEN UNIVERSITY   (China)

^e DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

Author keywords

Breast cancer; Cancer stem like cell; Cell cycle; Flubendazole; Tubulin

Indexed keywords

ANTHELMINTIC AGENT; BETA CATENIN; CD24 ANTIGEN; CYCLIN D1; CYTOKERATIN 18; DOXORUBICIN; FLUBENDAZOLE; FLUOROURACIL; HERMES ANTIGEN; NERVE CELL ADHESION MOLECULE; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; VIMENTIN; ANTINEMATODAL AGENT; ANTINEOPLASTIC AGENT; MEBENDAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER STEM CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; CYCLIND1 GENE; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; DRUG STRUCTURE; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; M PHASE CELL CYCLE CHECKPOINT; MICROTUBULE ASSEMBLY; MIGRATION INHIBITION; MOUSE; NANOG GENE; NONHUMAN; OCT4 GENE; ONCOGENE C MYC; POLYMERIZATION; SOX2 GENE; ANALOGS AND DERIVATIVES; ANIMAL; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; MCF-7 CELL LINE; METABOLISM; NUDE MOUSE; PATHOLOGY; RANDOMIZATION; TUMOR CELL LINE;

ANIMALS; ANTINEMATODAL AGENTS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MCF-7 CELLS; MEBENDAZOLE; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; RANDOM ALLOCATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925686758     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3436     Document Type: Article

References (54)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90.
2. Kakarala M and Wicha MS. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol. 2008; 26(17):2813-2820.
3. Gianni L, Baselga J, Eiermann W, Porta VG, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Cussac AL, Bozhok A, Martinez-Agullo A, Greco M, Byakhov M, Lopez JJ, Mansutti M, et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol. 2009; 27(15):2474-2481.
4. Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100, 000 women in 123 randomised trials. Lancet. 2012; 379(9814):432-444.
5. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J and Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-715.
6. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J and Chang JC. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008; 100(9):672-679.
7. Phillips TM, McBride WH and Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006; 98(24):1777-1785.
8. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS and Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007; 1(5):555-567.
9. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003; 100(7):3983-3988.
10. Nicolini A, Ferrari P, Fini M, Borsari V, Fallahi P, Antonelli A, Carpi A and Miccoli P. Cancer stem cells: perspectives of new therapeutical approaches for breast cancer. Front Biosci (Schol Ed). 2011; 3:1486-1499.
11. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S and Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One. 2008; 3(8):e2888.
12. Bane A, Viloria-Petit A, Pinnaduwage D, Mulligan AM, O'Malley FP and Andrulis IL. Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers. Breast Cancer Res Treat. 2013; 140(1):195-205.
13. Yanamoto S, Yamada S, Takahashi H, Naruse T, Matsushita Y, Ikeda H, Shiraishi T, Seki S, Fujita S, Ikeda T, Asahina I and Umeda M. Expression of the cancer stem cell markers CD44v6 and ABCG2 in tongue cancer: effect of neoadjuvant chemotherapy on local recurrence. Int J Oncol. 2014; 44(4):1153-1162.
14. Blagosklonny MV. Target for cancer therapy: proliferating cells or stem cells. Leukemia. 2006; 20(3):385-391.
15. Blagosklonny MV. Cancer stem cell and cancer stemloids: from biology to therapy. Cancer Biol Ther. 2007; 6(11):1684-1690.
16. Zhang XY, Varthi M, Sykes SM, Phillips C, Warzecha C, Zhu W, Wyce A, Thorne AW, Berger SL and McMahon SB. The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell. 2008; 29(1):102-111.
17. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, Meister G and Hermeking H. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle. 2007; 6(13):1586-1593.
18. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, Wiggins JF, Bader AG, Fagin R, Brown D and Tang DG. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011; 17(2):211-215.
19. Lee DF, Su J, Ang YS, Carvajal-Vergara X, Mulero-Navarro S, Pereira CF, Gingold J, Wang HL, Zhao R, Sevilla A, Darr H, Williamson AJ, Chang B, Niu X, Aguilo F, Flores ER, et al. Regulation of embryonic and induced pluripotency by aurora kinase-p53 signaling. Cell Stem Cell. 2012; 11(2):179-194.
20. Yan M and Liu QQ. Targeted therapy: tailoring cancer treatment. Chin J Cancer. 2013; 32(7):363-364.
21. Ceballos L, Elissondo C, Sanchez Bruni S, Denegri G, Lanusse C and Alvarez L. Comparative performances of flubendazole and albendazole in cystic echinococcosis: ex vivo activity, plasma/cyst disposition, and efficacy in infected mice. Antimicrob Agents Chemother. 2011; 55(12):5861-5867.
22. Ceballos L, Virkel G, Elissondo C, Canton C, Canevari J, Murno G, Denegri G, Lanusse C and Alvarez L. A pharmacology-based comparison of the activity of albendazole and flubendazole against Echinococcus granulosus metacestode in sheep. Acta Trop. 2013; 127(3):216-225.
23. Ceballos L, Elissondo M, Bruni SS, Denegri G, Alvarez L and Lanusse C. Flubendazole in cystic echinococcosis therapy: pharmaco-parasitological evaluation in mice. Parasitol Int. 2009; 58(4):354-358.
24. Mackenzie CD and Geary TG. Flubendazole: a candidate macrofilaricide for lymphatic filariasis and onchocerciasis field programs. Expert Rev Anti Infect Ther. 2011; 9(5):497-501.
25. Dominguez-Vazquez A, Taylor HR, Greene BM, Ruvalcaba-Macias AM, Rivas-Alcala AR, Murphy RP and Beltran-Hernandez F. Comparison of flubendazole and diethylcarbamazine in treatment of onchocerciasis. Lancet. 1983; 1(8317):139-143.
26. Katiyar SK, Gordon VR, McLaughlin GL and Edlind TD. Antiprotozoal activities of benzimidazoles and correlations with beta-tubulin sequence. Antimicrob Agents Chemother. 1994; 38(9):2086-2090.
27. Lacey E. The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles. Int J Parasitol. 1988; 18(7):885-936.
28. Kralova V, Hanusova V, Stankova P, Knoppova K, Canova K and Skalova L. Antiproliferative effect of benzimidazole anthelmintics albendazole, ricobendazole, and flubendazole in intestinal cancer cell lines. Anticancer Drugs. 2013; 24(9):911-919.
29. Spagnuolo PA, Hu J, Hurren R, Wang X, Gronda M, Sukhai MA, Di Meo A, Boss J, Ashali I, Beheshti Zavareh R, Fine N, Simpson CD, Sharmeen S, Rottapel R and Schimmer AD. The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma. Blood. 2010; 115(23):4824-4833.
30. Zheng FM, Long ZJ, Hou ZJ, Luo Y, Xu LZ, Xia JL, Lai XJ, Liu JW, Wang X, Kamran M, Yan M, Shao SJ, Lam EW, Wang SW, Lu G and Liu Q. A novel small molecule aurora kinase inhibitor attenuates breast tumor-initiating cells and overcomes drug resistance. Mol Cancer Ther. 2014; 13(8):1991-2003.
31. Caldon CE, Lee CS, Sutherland RL and Musgrove EA. Wilms' tumor protein 1: an early target of progestin regulation in T-47D breast cancer cells that modulates proliferation and differentiation. Oncogene. 2008; 27(1):126-138.
32. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR and Morris AD. Metformin and reduced risk of cancer in diabetic patients. Br Med J. 2005; 330(7503):1304-1305.
33. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN and Gonzalez-Angulo AM. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009; 27(20):3297-3302.
34. Hirsch HA, Iliopoulos D and Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci USA. 2013; 110(3):972-977.
35. Bhat-Nakshatri P, Goswami CP, Badve S, Sledge GW, Jr. and Nakshatri H. Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity. Sci Rep. 2013; 3:2530.
36. Chaudhary PM and Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell. 1991; 66(1):85-94.
37. Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M, Dean M, Sharp JG and Cowan K. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res. 2002; 8(1):22-28.
38. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K and Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2-cancer cells are similarly tumorigenic. Cancer Res. 2005; 65(14):6207-6219.
39. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA and Brenner MK. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA. 2004; 101(39):14228-14233.
40. Hayashida T, Jinno H, Kitagawa Y and Kitajima M. Cooperation of cancer stem cell properties and epithelial-mesenchymal transition in the establishment of breast cancer metastasis. J Oncol. 2011; 2011:591427.
41. Zubeldia IG, Bleau AM, Redrado M, Serrano D, Agliano A, Gil-Puig C, Vidal-Vanaclocha F, Lecanda J and Calvo A. Epithelial to mesenchymal transition and cancer stem cell phenotypes leading to liver metastasis are abrogated by the novel TGFbeta1-targeting peptides P17 and P144. Exp Cell Res. 2013; 319(3):12-22.
42. Papi A, Guarnieri T, Storci G, Santini D, Ceccarelli C, Taffurelli M, De Carolis S, Avenia N, Sanguinetti A, Sidoni A, Orlandi M and Bonafe M. Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells. Cell Death Differ. 2012; 19(7):1208-1219.
43. Ventayol M, Vinas JL, Sola A, Jung M, Brune B, Pi F, Mastora C and Hotter G. miRNA let-7e targeting MMP9 is involved in adipose-derived stem cell differentiation toward epithelia. Cell Death Dis. 2014; 5:e1048.
44. Sommers CL, Byers SW, Thompson EW, Torri JA and Gelmann EP. Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat. 1994; 31(2-3):325-335.
45. Paccione RJ, Miyazaki H, Patel V, Waseem A, Gutkind JS, Zehner ZE and Yeudall WA. Keratin down-regulation in vimentin-positive cancer cells is reversible by vimentin RNA interference, which inhibits growth and motility. Mol Cancer Ther. 2008; 7(9):2894-2903.
46. Squires S, Fisher M, Gladstone O, Rogerson S, Martin P, Martin S, Lester H, Sygall R and Underwood N. Comparative efficacy of flubendazole and a commercially available herbal wormer against natural infections of Ascaridia galli, Heterakis gallinarum and intestinal Capillaria spp. in chickens. Vet Parasitol. 2012; 185(2-4):352-354.
47. Kohri N, Yamayoshi Y, Xin H, Iseki K, Sato N, Todo S and Miyazaki K. Improving the oral bioavailability of albendazole in rabbits by the solid dispersion technique. J Pharm Pharmacol. 1999; 51(2):159-164.
48. Liu Y, Wang XQ, Ren WX, Chen YL, Yu Y, Zhang JK, Bawudong D, Gu JP, Xu XD and Zhang XN. Novel albendazole-chitosan nanoparticles for intestinal absorption enhancement and hepatic targeting improvement in rats. J Biomed Mater Res B Appl Biomater. 2013; 101(6):998-1005.
49. Castro N, Marquez-Caraveo C, Brundage RC, Gonzalez-Esquivel D, Suarez AM, Gongora F, Jara A, Urizar J, Lanao JM and Jung H. Population pharmacokinetics of albendazole in patients with neurocysticercosis. Int J Clin Pharmacol Ther. 2009; 47(11):679-685.
50. Millour J, de Olano N, Horimoto Y, Monteiro LJ, Langer JK, Aligue R, Hajji N and Lam EW. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. Mol Cancer Ther. 2011;10(6):1046-1058.
51. Lu Y, Lu J, Li X, Zhu H, Fan X, Zhu S, Wang Y, Guo Q, Wang L, Huang Y, Zhu M and Wang Z. MiR-200a inhibits epithelial-mesenchymal transition of pancreatic cancer stem cell. BMC Cancer. 2014; 14:85.
52. Wu YC, Yen WY, Ho HY, Su TL and Yih LH. Glyfoline induces mitotic catastrophe and apoptosis in cancer cells. Int J Cancer. 2010; 126(4):1017-1028.
53. Digirolamo CM, Stokes D, Colter D, Phinney DG, Class R and Prockop DJ. Propagation and senescence of human marrow stromal cells in culture: a simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate. Br J Haematol. 1999; 107(2):275-281.
54. Ding WQ, Liu B, Vaught JL, Palmiter RD and Lind SE. Clioquinol and docosahexaenoic acid act synergistically to kill tumor cells. Mol Cancer Ther. 2006; 5(7):1864-1872.